Case Report (n=1)
Giant cell myocarditis must be considered in the differential diagnosis of acute, refractory heart failure even following COVID-19 vaccination, as early endomyocardial biopsy and immunosuppression are life-saving.
May support immunosuppression plus Impella in biopsy-proven giant cell myocarditis; leaves open generalizability and any vaccine link.
The classic features of giant-cell myocarditis (GCM) are subacute, refractory congestive heart failure (CHF), and arrhythmia, although atypical presentations are common. Here, we report the case of a 62-year-old woman with CHF symptoms after a recent coronavirus disease 19 (COVID-19) vaccination, initially misdiagnosed as post-vaccine myocarditis. Rapid deterioration into cardiogenic shock resulted in endomyocardial biopsy, revealing GCM. Immunosuppressive therapy was initiated, and her cardiac function improved.
No takes yet. Share an insight, caveat, or question.
Baweja et al. (2023) conducted a case report in Giant cell myocarditis (n=1). Immunosuppressive therapy and mechanical circulatory support was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: